Bavarian Nordic Stock Price

BAVA Community Fair Values

• AN

  

  AnalystConsensusTarget

  Consensus Narrative from 2 Analysts

  VIMKUNYA Launch Will Open Markets, But Approval Delays Could Impact Revenues

  Key Takeaways Expansion in public preparedness and successful vaccine launches could significantly enhance revenue streams through government contracts and new territories. Advancements in new vaccine candidates indicate promising pipeline potential, supporting future revenue growth and market expansion.

  DKK 234.50

  FV

  1.3% overvalued intrinsic discount

  -2.71%

  Revenue growth p.a.

  0users have liked this narrative

  0users have commented on this narrative

  30users have followed this narrative

  8 days ago author updated this narrative
• AN

  

  AnalystLowTarget

  Consensus Narrative from 2 Analysts

  Dependence On Key Contracts Will Hamper Performance Yet Suggest Promise

  Key Takeaways Reliance on government contracts and a few high-value vaccines makes future revenues vulnerable to shifting spending priorities and competitive pressures. Manufacturing, regulatory, and demand uncertainties could cause volatile earnings and prevent expected margin improvements, despite efforts to diversify and scale operations.

  DKK 225.00

  FV

  5.6% overvalued intrinsic discount

  -4.17%

  Revenue growth p.a.

  0users have liked this narrative

  0users have commented on this narrative

  0users have followed this narrative

  9 days ago author updated this narrative
• AN

  

  AnalystHighTarget

  Consensus Narrative from 2 Analysts

  Rising Global Vaccine Demand Will Spur Progress But Face Headwinds

  Key Takeaways Accelerated manufacturing and strong travel health performance suggest margins and revenues may surpass expectations, signaling potential for significant long-term upside. Unique vaccine capabilities and expanding portfolio position the company to benefit from global health trends and increasing market opportunities, driving superior operational and financial growth.

  DKK 244.00

  FV

  2.7% undervalued intrinsic discount

  -2.34%

  Revenue growth p.a.

  0users have liked this narrative

  0users have commented on this narrative

  0users have followed this narrative

  9 days ago author updated this narrative